Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cancer Manag Res ; 12: 10771-10779, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33149682

RESUMEN

BACKGROUND: Propofol is a common clinical intravenous anesthetic. In the last few years, studies have revealed that propofol not only has good anesthetic effect but also has certain anticancer effect. However, its role in stomach cancer (SC) and related mechanisms are still under investigation. OBJECTIVE: This study was designed to determine the effect of propofol on SC and its related mechanisms. METHODS: Purchased SC cells were treated with propofol at different concentrations (5, 10, and 20 µg/mL), miR-205 overexpression, and YAP1 inhibition. Then, the Cell Counting Kit-8 (CCK8), Transwell, and flow cytometry were carried out to determine the biological behavior changes of treated cells and the expression of miR-205 and YAP1 after treatment. RESULTS: Propofol (10 µg/mL and 20 µg/mL) inhibited the growth of SC cells and promoted their apoptosis, and overexpressing miR-205 or inhibiting YAP1 can exert the same effects. In addition, propofol (10µg/mL and 20µg/mL) up-regulated miR-205 in SC cells. The dual-luciferase reporter assay revealed that YAP1 could be targeted and regulated by miR-205, and the rescue assay revealed that inhibiting miR-205 or overexpressing YAP1 could weaken the effect of propofol on the biological behaviors of SC cells. CONCLUSION: Propofol can strongly suppress the proliferation and invasion of SC cells and induce their apoptosis via the miR-205/YAP1 axis.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA